These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29027195)

  • 1. TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.
    Qin S; Liu D; Kohli M; Wang L; Vedell PT; Hillman DW; Niu N; Yu J; Weinshilboum RM; Wang L
    Clin Pharmacol Ther; 2018 Jul; 104(1):201-210. PubMed ID: 29027195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 Transcriptional Regulation by Testis-Specific Y-Encoded-Like Protein: Identification of Novel Upstream Transcription Factors.
    Shivaram S; Gao H; Qin S; Liu D; Weinshilboum RM; Wang L
    Drug Metab Dispos; 2023 Jan; 51(1):1-7. PubMed ID: 36153008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Binder M; Zhang BY; Hillman DW; Kohli R; Kohli T; Lee A; Kohli M
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
    Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
    Crucitta S; Del Re M; Paolieri F; Bloise F; Sbrana A; Sammarco E; Mercinelli C; Cucchiara F; Fontanelli L; Galli L; Danesi R
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):527-533. PubMed ID: 32945940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials.
    Cao Q; Bai P; Shi D; Liao J; Shi H; Xing Y; Chen K; Zhang X
    J Cancer Res Ther; 2020 Sep; 16(5):990-1001. PubMed ID: 33004739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C; Jimeno A; Kessler ER
    Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
    Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
    Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
    Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP17A1 inhibitors in castration-resistant prostate cancer.
    Gomez L; Kovac JR; Lamb DJ
    Steroids; 2015 Mar; 95():80-7. PubMed ID: 25560485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.
    Harshman LC; Taplin ME
    Adv Ther; 2013 Aug; 30(8):727-47. PubMed ID: 23979793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
    Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
    Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline Variant in
    Hahn AW; Gill DM; Poole A; Nussenzveig RH; Wilson S; Farnham JM; Stephenson RA; Cannon-Albright LA; Maughan BL; Agarwal N
    Mol Cancer Ther; 2019 Mar; 18(3):726-729. PubMed ID: 30587554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
    Scott LJ
    Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
    Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
    Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer.
    Wang Y; Dason S; Shayegan B
    Can J Urol; 2016 Aug; 23(4):8388-94. PubMed ID: 27544566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients.
    Zhai Q; Moes DJAR; van Gelder T; van der Lee M; Sanders JS; Bemelman FJ; de Fijter JW; Klein K; Schwab M; Swen JJ
    Clin Transl Sci; 2024 Feb; 17(2):e13729. PubMed ID: 38380703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.